All posts by medical

Neuroscience Market Growth Factor with Key Drivers Analysis till 2026 | GE Healthcare, Siemens Healthineers, Noldus Information Technology, Mightex…

The Global Neuroscience Market share held by the notable professionals of the business and conveys a full perspective on the focused scene. This Neuroscience market is ordered into various sections with the complete examination of each concerning the topography for the investigation time frame. In focus of the verifiable investigation and evaluations of future prospects depend on top to bottom research. This Neuroscience report quickly gives the market patterns, size, development, and estimation for the period 2021-2026.

The report identifies the market share/size and factors controlling the evolution of the market. Additionally, the Neuroscience market research report studies the market scope, industry segment, key drivers for development, major segments, and SWOT Analysis. Moreover, this complete research report provides value in terms of segmental analysis and estimations on the market across regional levels as well as from a universal perspective. Additionally, this report provides insights on the factors that are driving and restraining the demand of Neuroscience market.

Major players covered in this report:

GE HealthcareSiemens HealthineersNoldus Information TechnologyMightex BioscienceThomas RECORDING GmbHBlackrock MicrosystemsTucker-Davis TechnologiesPlexonPhoenix Technology GroupNeuroNexusAlpha Omega

Get a Sample Copy of the report @https://www.reporthive.com/request_sample/2298403

Neuroscience Market Competitive Landscape:The Report on Neuroscience depicts the current & future growth trends of this business besides outlining details pertaining to the myriad geographies that are a part of the regional landscape of Market. The report further elucidates intricate details regarding the supply and demand analysis, Market share, growth statistics and contributions by leading industry players of Market.

Segmentation by Product:

Whole Brain ImagingNeuro-MicroscopyElectrophysiology TechnologiesNeuro-Cellular ManipulationStereotaxic SurgeriesAnimal BehaviorOthers

Segmentation by Application:

HospitalsDiagnostic LaboratoriesResearch InstitutesOthers

Major regions covered in the report:

North America [U.S., Canada, Mexico]Europe [Germany, UK, France, Italy, Rest of Europe]Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]South America [Brazil, Argentina, Rest of Latin America]Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]

Why buy a market analysis report on Neuroscience?: Comprehensive and comfortable for our viewers to understand the market report Neuroscience by offering in-depth information through in-depth analysis: The report includes a market scenario, a market structure, market constraints, a study statistics in a market-based market.: It allows tank buffer stainless steel key players to obtain informative data on market trends, upstream and downstream of the upcoming market.: Historical and futuristic information taken into account when running on the Neuroscience types of products, applications and geographical areas: Detailed information on market classification, main opportunities and market developments, as well as on market restrictions and the major challenges facing the market.: Neuroscience Report includes events associated with manufacturing and distribution networks, as well as cost analysis.

For More Information or Query or Customization Before Buying, Visit at -:https://www.reporthive.com/request_customization/2298403

Table of Contents Chapter 1: The report starts with an overview of the global Neuroscience market and highlights of the research study. Chapter 2: Here, the report provides a detailed study of growth driving factors, market challenges, trends, and opportunities. Chapter 3: This chapter offers complete segmental analysis where product and application segments are analyzed in detail. Chapter 4: This section of the report deals with key regions and their potential for growth in the global Neuroscience market. Chapter 5: Here, the report provides deep company profiling of leading players. This chapter also provides an extensive study of the competitive landscape. Chapter 6: Readers are provided with accurate forecasts of production and production value growth in the global Neuroscience market. Chapter 7: The report also provides projections related to consumption in different regions and across the globe. Chapter 8: Here, the authors of the report have discussed about key sales channels and the industry value chain. This chapter also includes comprehensive customer and distributor analysis. Chapter 9: This part of the report sheds light on significant aspects of the global Neuroscience market through Porters Five Forces analysis and PESTLE analysis. Chapter 10: Finally, the report concludes with a summary of important findings about the global Neuroscience market.

About us:

Our research base consists of a wide spectrum of premium market research reports. Apart from comprehensive syndicated research reports, our in-house team of research analysts leverages excellent research capabilities to deliver highly customized tailor-made reports. The market entry strategies presented in our reports has helped organizations of all sizes to generate profits by making timely business decisions. The research information including market size, sales, revenue, and competitive analysis offered, is the product of our excellence in the market research domain.

https://neighborwebsj.com/

Read the original post:
Neuroscience Market Growth Factor with Key Drivers Analysis till 2026 | GE Healthcare, Siemens Healthineers, Noldus Information Technology, Mightex...

Celebrate the Third Annual Medical Genetics Awareness Week April 13-16, 2021 – PRNewswire

BETHESDA, Md., Feb. 11, 2021 /PRNewswire/ --The third annual Medical Genetics Awareness Week will be celebrated April 1316, 2021. Through Medical Genetics Awareness Week, the American College of Medical Genetics and Genomics (ACMG) aims to promote awareness of the importance of medical genetics professionals on the healthcare team, including medical geneticists, laboratory geneticists, genetic counselors, nurses and physician assistants. The theme of Medical Genetics Awareness Week is "Celebrating the Contributions of the Entire Medical Genetics Team to Patient Care and Public Health."

New for 2021 are high-quality face masks and a Zoom virtual background to help individuals "Share Your Medical Genetics Pride." Participants can share their pictures to social media wearing a Medical Genetics Awareness Week face mask (free for ACMG members) or a Medical Genetics Awareness Week hashtag button; using a new Medical Genetics Awareness Week Zoom virtual background; or displaying a Medical Genetics Awareness Week sticker.

Since 2019, Medical Genetics Awareness Week has brought together people from across the globe to celebrate the important work of medical genetics professionals. Medical Genetics Awareness Week is celebrated to recognize the critical contributions that medical genetics healthcare professionals make in the diagnosis, management and prevention of genetic diseases, and the difference these professionals make in the lives of patients and families. Medical Genetics Awareness Week is also intended to educate other healthcare professionals and students and trainees on who medical geneticists are, how they are trained and what they do in the clinic and laboratory.

Also new for 2021 are themed days that will include a Diversity Day and a Student and Trainee Day. Follow Medical Genetics Awareness Week on social media by searching the #MedicalGeneticsAwareness hashtagand sign up to receive news and updates about Medical Genetics Awareness Week by clicking here. Log in (or create a free ACMG account) and, on the privacy preferences page, opt in to receive news and updates about Medical Genetics Awareness Week.

"Medical genetics and genomics is now deeply wedged into nearly all disciplines of medicine," said ACMG President Anthony R. Gregg, MD, MBA, FACOG, FACMG. "It is a natural extension that we remind the public and all healthcare professionals that those of us who practice medical genetics in clinics, clinical laboratories and research environments work tirelessly and with great enthusiasm. Our singular common goal is to bring accurate genetic information to the bedside that will improve people's lives."

Events related to Medical Genetics Awareness Week will be held during the ACMG Annual Clinical Genetics Meeting A Virtual Experience, April 1316, 2021, but participants don't need to be a meeting registrant to participate in the week's activities. The ACMG Annual Meeting is the largest conference specifically for clinical and laboratory geneticists in the United States. Those interested in collaborating with ACMG to celebrate Medical Genetics Awareness Week, holding their own events or becoming an "ambassador" for medical genetics are invited to email ACMG Communications Coordinator Reymar Santos at [emailprotected]for more information.

"Medical genetics is for all of us," said Max Muenke, MD, FACMG, ACMG'schief executive officer. "I am delighted to celebrate my colleagues in this important field: genetic counselors, laboratory geneticists, medical geneticists, and other allied healthcare professionals who are committed to optimal patient care."

Visit the Medical Genetics Awareness Week web pageson ACMG's website for resources and tips designed to support the week's celebrationsand to join the Medical Genetics Awareness Week email list. When posting on social media, participants are encouraged to tag @TheACMG and include the following hashtags in posts related to Medical Genetics Awareness Week:

#MedicalGeneticsAwareness#IamaMedicalGeneticist#FutureGeneticsProfessional#IamaLabGeneticist#IamaGeneticCounselor#IamaGeneticsPA#IamaNurseinGenetics#IamaGeneticsNP

About the American College of Medical Genetics and Genomics (ACMG) and ACMG Foundation

Founded in 1991, the American College of Medical Genetics and Genomics (ACMG) is the only nationally recognized medical society dedicated to improving health through the clinical practice of medical genetics and genomics and the only medical specialty society in the US that represents the full spectrum of medical genetics disciplines in a single organization. The ACMG is the largest membership organization specifically for medical geneticists, providing education, resources and a voice for more than 2,400 clinical and laboratory geneticists, genetic counselors and other healthcare professionals, nearly 80% of whom are board certified in the medical genetics specialties. ACMG's mission is to improve health through the clinical and laboratory practice of medical genetics as well as through advocacy, education and clinical research, and to guide the safe and effective integration of genetics and genomics into all of medicine and healthcare, resulting in improved personal and public health. Four overarching strategies guide ACMG's work: 1) to reinforce and expand ACMG's position as the leader and prominent authority in the field of medical genetics and genomics, including clinical research, while educating the medical community on the significant role that genetics and genomics will continue to play in understanding, preventing, treating and curing disease; 2) to secure and expand the professional workforce for medical genetics and genomics; 3) to advocate for the specialty; and 4) to provide best-in-class education to members and nonmembers. Genetics in Medicine, published monthly, is the official ACMG journal. ACMG's website (www.acmg.net) offers resources including policy statements, practice guidelines, educational programs and a 'Find a Genetic Service' tool. The educational and public health programs of the ACMG are dependent upon charitable gifts from corporations, foundations and individuals through the ACMG Foundation for Genetic and Genomic Medicine.

Kathy Moran, MBA[emailprotected]

SOURCE American College of Medical Genetics and Genomics

http://www.acmg.net

See more here:
Celebrate the Third Annual Medical Genetics Awareness Week April 13-16, 2021 - PRNewswire

People in the News: New Appointments at Sema4, Sophia Genetics, Qiagen, More – GenomeWeb

Sema4: Isaac Ro

Isaac Ro has been appointed as CFO of Sema4. Previously, he was CFO of Thrive Earlier Detection, which was recently acquired by Exact Sciences. Prior to that, he led the US medical technology team at Goldman Sachs, where he covered life science tools, diagnostics, and medical technology. Before that, he held a similar role at SVB Leerink.

Sophia Genetics: Ross Muken

Originally posted here:
People in the News: New Appointments at Sema4, Sophia Genetics, Qiagen, More - GenomeWeb

New nutrition from NGX is personalised for your genetics – road.cc

Nutri-Genetix (NGX) has released a genetically personalised daily nutrition shake that it says will offer enhanced performance and boosted immunity as it is tailored to each rider's DNA after a swab test is taken.

NGX says it relies on nutrigenetics, which aims to understand how people metabolise and process different nutrients based on their genetic makeup.

A persons DNA can have a significant effect on how their bodyuses nutrients, and everyones DNA has a direct association with how their nutrients are absorbed, transported, activated and eliminated from their bodies, says NGX.

Consumers need to take a swab from the inside of their cheek and from there NGX runs a genetic test which the brand says can identify your optimal dietary needs.

The lab then analyses over 30 SNPs (single-nucleotide polymorphisms) which, according to the brand, determines how the individual metabolises and processes different nutrients, as well as sensitivities to certain foods and their bodys detoxification process. An in-depth report is produced highlighting the key areas the shake needs to target and it is delivered for your own personal use.

The ratio of macronutrients in each shake (the proteins, carbohydrates and fats) and micronutrients (vitamins and minerals) is said to be designed specifically to optimise muscle performance and maximise fat loss, enabling people to achieve a lean, sculpted physique faster and more easily than with other supplements and shakes.

The recommended portion is 70g, two scoops' worth, of NGX BodyFuel each day, along with a balanced diet hitting your personal standard nutritional reference intake.

It comes unflavoured, but there are two add-ons: SuperBerry which is said to be antioxidant packed, fibre and vitamin rich, while the Cocoa & Coconut option is packed with good fats says NGX.

Alongside regular daily use of the BodyFuel, the NGX PowerPack recovery drink can be taken immediately after a workout. One 35g scoop, a blend of protein, carbohydrate and vegan-friendly creatine, is said to help you achieve optimal results and maximisesrecovery.

All NGX products are said to be made from naturally sourced, vegan-friendly ingredients and contain no artificial sweeteners, flavours or colouring, as well as being free from soy, lactose, gluten and GMO.

Now for prices. Well, NGX offer a Starter Pack at 129.99 which includes the DNA Nutrition Test and DNA Report; 2x 500g pouches of NGX BodyFuel, 200g of flavour and an NGX t-shirt and shaker.

Subscription prices start from 34.99. Receive a free DNA test (worth 99.99) and personalised nutrition report when you subscribe to BodyFuel and you can chose the amount of product you desire...

http://www.nutri-genetix.com

Read more:
New nutrition from NGX is personalised for your genetics - road.cc

Myriad Genetics to Participate in Multiple Upcoming Health and Technology Conferences – GlobeNewswire

SALT LAKE CITY, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it will participate at multiple upcoming health and technology conferences, sharing insights on how the company is intensifying its focus on serving patients and healthcare providers in Womens Health, Oncology and Mental Health.

Paul J. Diaz, president and CEO at Myriad Genetics, and R. Bryan Riggsbee, CFO, will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 19 at 10:30 a.m. EST.

On February 24, 2021, Mr. Riggsbee will participate in a fireside chat at the Leerink Global Healthcare Conference at 5:00 p.m. EST.

On March 2, 2021, Mr. Diaz will participate in a fireside chat at the Cowen Annual Healthcare Conference at 9:50 a.m. EST.

The presentations will be available through a live audio webcast link in the investor information section of Myriads website at http://www.myriad.com.

About Myriad GeneticsMyriad Genetics, Inc. is a leading genetic testing and precision medicine company dedicated to improving health and transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Read the original post:
Myriad Genetics to Participate in Multiple Upcoming Health and Technology Conferences - GlobeNewswire

Global Animal Genetics Market Forecast to 2027 by Product (Poultry, Porcine, Bovine, Canine), Material (Semen and Embryo), and Services (DNA Typing,…

DUBLIN--(BUSINESS WIRE)--The "Animal Genetics Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Product (Poultry, Porcine, Bovine, Canine, and Others), Genetic Material (Semen and Embryo), and Services (DNA Typing, Genetic Trait Tests, Genetic Disease Tests, and Others) and Geography." report has been added to ResearchAndMarkets.com's offering.

Genetic material and Services the market is expected to reach US$ 7,705.23 million by 2027 from US$ 4,778.67 million in 2019. The market is estimated to grow at a CAGR of 6.3% from 2020 to 2027.

Based on product, the market is segmented into poultry, porcine, bovine, canine, and others. In 2019, the porcine segment accounted for the highest share of the market. Growth of this segment is attributed to rise in production of porcine and increase in pork consumption across the globe. The same segment is likely to register highest CAGR in the global animal genetics market during the forecast period.

In terms of genetic material, the animal genetics market is segmented into embryo and semen. The embryo segment held the largest share of the market in 2019, whereas the semen segment is anticipated to register the highest CAGR of 7.0% in the market during the forecast period.

COVID-19 pandemic has become the most significant challenge across the world. This challenge would be frightening, especially in developing countries across the globe, as it may lead to reducing imports due to disruptions in global trade, which further increases the shortages of meat and dairy product supplies, resulting in a considerable price increase. Asian countries such as China, South Korea, and India are severely affected due to COVID-19 outbreak.

NEOGEN Corporation, HENDRIX GENETICS BV, Zoetis Inc., Genus, TOPIGS NORSVIN, Envigo, VetGen, ANIMAL GENETICS INC., ALTA GENETICS INC., and Groupe Grimaud are among the leading companies operating in the animal genetics market.

Key Topics Covered:

1. Introduction

1.1 Scope of the Study

1.2 Report Guidance

1.3 Market Segmentation

2. Animal Genetics Market - Key Takeaways

3. Research Methodology

4. Animal Genetics Market - Market Landscape

4.1 Overview

4.2 PEST Analysis

4.3 Expert Opinions

5. Animal Genetics Market - Key Market Dynamics

5.1 Market Drivers

5.1.1 Growing Preference for Animal Derived Proteins Supplements and Food Products.

5.1.2 Rising Adoption of Progressive Genetic Practices Such as Artificial Insemination (AI) and Embryo Transfer

5.2 Market Restraints

5.2.1 Limited Number of Skilled Professionals in Veterinary Research

5.2.2 Stringent Government Regulations for Animal Genetics

5.3 Market Opportunities

5.3.1 Innovations in Phenotyping Services

5.4 Future Trends

5.4.1 Significant Investments in R&D and Expansions Undertaken by Market Players

5.5 Impact Analysis

6. Animal Genetics Market - Global Analysis

6.1 Global Animal Genetics Marker Revenue Forecast and Analysis

6.2 Global Animal Genetics Market, By Geography - Forecast And Analysis

6.3 Market Positioning of Key Players

7. Animal Genetics Market Analysis - By Product

7.1 Overview

7.2 Animal Genetics Market Revenue Share, by Product (2019 and 2027)

7.3 Poultry

7.4 Porcine

7.5 Bovine

7.6 Canine

8. Animal Genetics Market Analysis - By Genetic Material

8.1 Overview

8.2 Animal Genetics Market Revenue Share, by Genetic Material(2019 and 2027)

8.3 Semen

8.4 Embryo

9. Animal Genetics Market Analysis - By Service

9.1 Overview

9.2 Animal Genetics Market Share, by Service, 2019 and 2027, (%)

9.3 DNA Typing

9.4 Genetic Trait Tests

9.5 Genetic Disease Tests

10. Animal Genetics Market Analysis and Forecasts To 2027 - Geographical Analysis

11. Impact of COVID-19 Pandemic On Global Animal Genetics Market

11.1 North America: Impact Assessment of COVID-19 Pandemic

11.2 Europe: Impact Assessment of COVID-19 Pandemic

11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic

11.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

12. Industry Landscape

12.1 Overview

12.2 Growth Strategies Done by the Companies in the Market, (%)

12.3 Organic Developments

12.3.1 Overview

12.4 Inorganic Developments

12.4.1 Overview

13. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/6ynx7z

Read this article:
Global Animal Genetics Market Forecast to 2027 by Product (Poultry, Porcine, Bovine, Canine), Material (Semen and Embryo), and Services (DNA Typing,...

Fulgent Genetics Is On Fire – Are We Getting Squeezed Or Is Fulgent A Stud? – Seeking Alpha

To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser.Is this happening to you frequently? Please report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Reference ID:

Follow this link:
Fulgent Genetics Is On Fire - Are We Getting Squeezed Or Is Fulgent A Stud? - Seeking Alpha

New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics’ Prolaris test to Guide Treatment for Prostate…

SALT LAKE CITY, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today additional data further validating the prognostic power of its Prolaris test and its ability to help accurately predict which men with more aggressive prostate cancer will benefit from intensification of therapy and which patients may safely avoid such treatments. This second validation study was presented during an oral presentation at the American Society of Clinical Oncology Genitourinary Cancer Symposium (ASCO-GU) by Jonathan Tward M.D., Ph.D, associate professor in the Department of Radiation Oncology at the University of Utah.

According to estimates by the American Cancer Society, 248,530 new cases of prostate cancer are expected to be diagnosed this year in the U.S. While early screening tests have helped reduce the mortality rate, they can often result in overdiagnosis and overtreatment of a disease that is clinically insignificant. The Prolaris test can more accurately predict the aggressiveness of the cancer allowing for more precise treatment and avoidance of more intense therapies with a patients parallel morbidities.

There are many viable treatment paths for men with prostate cancer, said Dr. Tward. This new data helps distinguish the most appropriate personalized treatment path for each patient based on how their specific tumor is behaving. For some men, this means being able to avoid overtreating patients with therapies including hormone treatment that can momentously impact their quality of life, while still appropriately treating their prostate cancer.

The new data comes from a second study following previous data, recently published in Clinical Genitourinary Cancer in January 2021, that incorporated men treated surgically or with radiation therapy. This new study combined a Prolaris molecular risk score threshold with a clinical model for predicting a patients benefit from androgen deprivation therapy. Prolaris determined that about one of every two men with unfavorable intermediate-risk and one of every five men with high-risk prostate cancer are below the proposed threshold associated with aggressive disease and can therefore safely be treated with less intense therapy while maintaining the benefits of treatment. Additional key findings revealed that the Prolaris test was an accurate predictor of progression to metastatic disease.

Myriad Genetics was the first company to offer a test that directly measures the molecular biology of an individual patients prostate cancer, said Todd D. Cohen, M.D., vice president of Medical Affairs for Urology at Myriad Genetics. This study by Dr. Tward and his team is another strong validation of the prognostic power of the Prolaris test and our ongoing commitment to providing healthcare professionals with the tools needed to determine the most effective treatments and monitoring strategies for each patient.

In March 2020, the National Comprehensive Cancer Network updated its professional guidelines to include biomarker testing for unfavorable intermediate and high-risk patients with prostate cancer. With the updated guidelines, Prolaris was one of only two prognostic tests to be considered for those expanded indications. Approximately 60% of men with prostate cancer currently have insurance or Medicare access to Prolaris, and Myriad continues to work toward expanding access so that every man who is facing difficult treatment decisions will be able to utilize the full benefits of the test.

About ProlarisProlaris is a genetic test developed by Myriad Genetics that directly measures tumor cell growth. The Prolaris test paired with other clinical and pathologic variables provides the level of aggressiveness of a patients individual prostate cancer and assesses risk of death or the development of metastatic disease from prostate cancer. For more information visit: http://www.prolaris.com.

About Myriad GeneticsMyriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit the Company's website:www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the validation study presented during at ASCO-GU by Jonathan Tward M.D., Ph.D; expanding access so that every man who is facing difficult treatment decisions will be able to utilize the full benefits of the Prolaris test; and the Companys strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2020, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Excerpt from:
New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics' Prolaris test to Guide Treatment for Prostate...

Three Behaviors That Isolate Philanthropists (And Make Them Less Effective) – Forbes

We need to be honest with ourselves about exactly where and how we are falling short

When nobody is offering you constructive criticism, take an honest look in the mirror.

I'd hazard a guess that in philanthropy circles, people arent often calling each other out for being delusional. That's why I wrote a book on it. Its called Delusional Altruism. In a nutshell, its about human behaviors were not even aware of that get in the way of transformational change. Its also about how to replace those behaviors with ways of working that are much more effective.

At a time of deep social anxiety as we grapple with a pandemic, police brutality and systemic racial inequalities brought into even starker relief because of COVID-19, we need to be honest with ourselves about exactly where and how we are falling short. We dont have the time or luxury to live in our own alternate reality.

While most philanthropists are eager to do the right thing, the hard part is changing something that you dont even know youre doing. So, here are three very common blind spots to recognize, and what to do instead. These changes will lead you to greater opportunities, more powerful networks, and increased resources and support. In other words, by doing these things youll pivot away from too much isolation, privilege and power, and create more inclusion and equitable impact.

1. You have a scarcity mentality. Instead, embrace abundance.

If you routinely do everything on the cheap, without investing in the infrastructure or long-term health of your organization and its people, you're limiting yourself with restrictions instead of building yourself up with opportunities. Although your heart might be in the right place thinking more money will go to the cause, you are doing more harm than good.

This mentality often gets extended to grantees, with little to no funding offered for things that can help them grow in impact and effectiveness like operating expenses, leadership development or technology. Having a stranglehold on opportunity creates a massive imbalance of power and leaves those on the ground spending their time grasping for limited resources.

An alternative to this reality is an abundance mindset. It's not about throwing money around, but instead focusing on becoming stronger. Being proactively generous with things like your leadership, reputation, experience and connections positions you and your collaborators to succeed in new ways. Taking risks, thinking big and investing in your capacity and talent and that of your grantees are other ways to unleash opportunity and the almost limitless human capacity to create and implement solutions.

2. Youre extraordinarily busy with little to show for it. Instead, quickly find your North Star.

Even if you have means, trying to figure out which way to go is one of life and philanthropy's significant challenges, especially when you want to make a substantial difference. So, absent a clear X-marks-the-spot, many organizations churn in relative solitude, putting out a mountain of good intentions and effort but without the corresponding impact. While many philanthropies are trying to rectify this with strategy focused on long-term systemic change, progress still remains elusive.

So how do you find your way? Instead of spending an outsized amount of time deliberating in the board room to create a three-to-five-year strategic plan, make strategy a vital but more short-term tool. In addition to being more helpful for galvanizing your team and collaborators toward a common goal, when a crisis hits, your plan won't become immediately obsolete. And you'll have the ability and experience to quickly adjust your strategy when new circumstances arise.

Creating a clear strategy for the next year requires having a clear mission (your reason for being), organizational values (your guiding beliefs that define your culture and behavior), and a vision (the future you want to help realize). Once you have these in place, you can determine the short-term sprints that get you closer to specific and progressive waypoints along your journey. Then comes implementationclearing out the things that are no longer a priority, assigning tasks, holding the team accountable, celebrating successes, learning, and adjusting your course.

3. You wield too much power. Instead, cede control and build trust.

You hold the resources that other people need. You are the Grantor and they are the grantee. Ultimately, it's a set-up for limiting honesty and trusting relationships. In addition to a more isolating, stressful and less fun environment for everyone, this power differential also sets philanthropies up for failure because they don't have enough feedback loops to understand how efforts may be falling short. If you are trying to reduce racial inequities, its another way to perpetuate the status quo because youre existing within a privileged and ignorant bubble. But you hold the power to remove these barriers.

You can do that by consciously working harder to build trusting relationships with your community, your grantees, essentially anyone who is a potential partner and collaborator in this work. Start by being your most authentic self. Own who you are and what you are good at and appreciate that same honesty in others. Say what you'll do and do what you say. Establish expectations from engagement to dollars and then follow through. And admit mistakes. When we make ourselves vulnerable, people lean in with recognition and understanding. Saying you don't know or figuring things out with your grantees as collaborators will change your relationships and what you can accomplish as a collective.

One key thing to remember is that relationship building takes time. Be patient. Find shared values and goals. Recognize power dynamics. And listen long and hard.

As Mahatma Gandhi said, "If you want to change the world, start with yourself." By seeing clearly the ways we hold ourselves and our collaborators back and then consciously changing, we create new and better realities for ourselves and the people around us. In times like these, it's this kind of momentum that will remake civil society into the inclusive engine for change we all know it has the potential to be.

Continued here:
Three Behaviors That Isolate Philanthropists (And Make Them Less Effective) - Forbes

Menstrual cycles and lunar cycles: Is there a link? – Medical News Today

For centuries, scholars and writers have speculated about the possibility of a link between lunar cycles and menses. And in 2021, it seems that the potential synchronicity between the two continues to fascinate.

Menstruation is a cyclical process, as are the phases of the Moon from new moon to waning crescent. Little wonder, then, that poets, philosophers, and scholars have, over the centuries, drawn parallels between the two, suggesting that they might be connected.

The mystique of the Moon and that of female bodies at a time when medicine was in its infancy led Greek philosopher Aristotle to claim, in the 4th century before the common era, that:

[T]he menses tend to occur naturally during the waning moon []. For this time of the month is colder and more humid because of the wasting and disappearance of the Moon.

Age-old parallels between the menstrual cycle and the phases of the moon have likely also led to some females referring to their periods as moon cycles to this day.

Is there really a link between lunar cycles and menstrual cycles? In this Special Feature, we investigate.

Popular belief and many works of literature suggest that there may be some synchronicity between menses and the phases of the Moon.

That may be based on the similarity of duration between menstrual cycles and lunar cycles.

One full revolution of the Moon around the Earth takes 27 days, 7 hours, and 43 minutes. A moon phase cycle, during which the amount of Moon surface that we are able to see from Earth waxes and wanes, takes 29.5 days.

The length of menstrual cycles can be in the range of 2530 days, with the median duration of a menstrual cycle being 28 days.

One 1986 study which Sung Ping Law, from the Department of Gynecology at the Canton Traditional Chinese Medical College in Guangzhou, conducted did seem to find a link between menstrual and lunar cycles.

The research, which appears in the journal Acta Obstetricia et Gynecologica Scandinavica, studied the cycles of 826 female participants, aged 1625 years, over 4 lunar months in different seasons.

The study concept, the author writes, was based on the concept of traditional Chinese medicine that human physiological rhythms display synergism with other natural rhythms.

Law found that, in the study cohort, a large proportion of menstruations occurred around the new moon. This led the researcher to deduce that ovulation periods tended to coincide with the full moon.

However, more recent research contradicts the notion that menstrual cycles often synch with moon phases.

For example, a year-long retrospective study from 2013 which appears in the journal Endocrine Regulations found no synchrony of lunar phases with the menstrual cycle.

This study monitored 980 menstrual cycles in 74 females of reproductive age over a calendar year. The authors say that the findings came in defiance of traditional beliefs.

A more recent study, which the company who program the period tracking app Clue commissioned in 2016, also concludes that synchrony between menstrual and moon cycles is a myth.

This research, which analyzed over 7.5 million menstrual cycles, suggests that periods most likely do not sync with the lunar cycle.

The researchers collected data on menstrual patterns from 1.5 million Clue users. Clue data scientist Dr. Marija Vlajic Wheeler analyzed them.

Looking at the data, we saw that period start dates fall randomly throughout the month, regardless of the lunar phase, says Dr. Wheeler.

Clues raw data and subsequent analysis are not available to the public.

A new study in the journal Science Advances, however, suggests that there may be more to the idea of synchrony between lunar phases and menstrual cycles than previous research may have indicated.

This small-scale study analyzed the menstrual patterns of 22 participants who had kept track of their period onset for up to 32 years.

Together, we had recordings of 15 women aged [35 years and younger] and of 17 women aged [over] 35 years, the researchers write.

Their study found that those whose menstrual cycles were longer than 27 days had intermittent synchrony with two of the Moons cycles: the luminance cycle and the gravimetric cycle.

The luminance cycle refers to the Moons different light intensity as its position in relation to the Sun changes and it passes through its different phases, from new moon to full moon.

The gravimetric cycle refers to the cyclical difference of the Moons pull on the Earth as it orbits around our planet. Since the Moons orbit is elliptical, sometimes it is more distant from the Earth, and sometimes it comes closer.

Its cycle from perigee (when it is closest to the Earth) to apogee (when it is farthest from the Earth) lasts 27.5 days. Depending on where it is in its orbit, the Moon exerts a different gravitational pull on different parts of the Earth.

A third lunar cycle the tropical month, or the mean time of the Moons revolution from any one point in its orbit back to that same point also seemed to be linked to period onset, though to a lesser degree, according to the study authors.

The team also notes that, while menstrual cycles intermittently synched with the Moon cycles, the likelihood of synchrony faded as the participants got older.

Overall, the researchers observed that the Moons light intensity cycle seemed to be the most influential lunar cycle in terms of its effect on menses onset.

We hypothesize that in ancient times, human reproductive behavior was synchronous with the Moon but that our modern lifestyle, notably our increasing exposure to artificial light, has changed this relation, they explain.

Medical News Today spoke to first study author Prof. Charlotte Frster, from the Neurobiology and Genetics Biocenter at the Julius-Maximilians University of Wrzburg in Germany.

We asked her what spurred her research interest in the possible synchrony between moon cycles and the menses.

As a chronobiologist, I am interested in all kind[s] of rhythms, and I was always fascinated by the coincidence of the lunar cycle length and the menstruation cycle length, she told us.

At the same time, she went on, it was very clear that most women appear not to be in synchrony with the moon at least not permanently. This brought me to the idea to investigate whether menses onset couples intermittently to the moon, and I started to ask women about long-term records of their menses onset.

Although her and her colleagues study may be small-scale, sourcing the necessary data to conduct it was no mean feat.

It took more than 10 years until I had collected the data from these 22 women, Prof. Frster explained.

Their study taps into much debated questions regarding how and to what extent human circadian rhythms or our body clocks, which regulate our biological patterns relate to cycles from our natural environment.

Previous studies, including a recent one in the Journal of the Endocrine Society, have looked at fluctuations in melatonin levels in the blood throughout the menstrual cycle.

These have shown that levels of melatonin which is a hormone key to regulating circadian rhythms, and especially the sleep-wake cycle peak just before the onset of menses and decline, overall, the closer a female gets to menopause.

There is also some evidence to suggest that a full moon influences sleep, essentially disrupting sleep duration and quality. One 2013 study in the journal Current Biology suggests that participants slept less on a full moon night, and their melatonin levels also decreased.

Furthermore, there is some evidence to suggest that artificial light can disrupt sleep-wake cycles and have a negative impact on sleep duration and quality.

However, is there any evidence in support of Prof. Frster and colleagues hypothesis that exposure to artificial light has affected females natural synchronicity with lunar cycles over time?

Why and how might exposure to artificial light affect menstrual cycles? MNT asked Prof. Frster. This is a difficult question, and I cannot answer it yet, she replied.

Despite existing evidence that suggests that artificial light affects various aspects of circadian rhythms, research into how it might interfere with menstrual cycles is lacking, she explained.

What we know from circadian rhythms is that their period is strongly affected by light. Depending on the species, [this] period becomes shorter or longer with increasing light intensity. Obviously, this also applies to monthly rhythms, such as the menstruation cycle. In circadian rhythms, light interferes with the molecular mechanisms that generate them. For monthly rhythms, the molecular mechanisms are not yet known. Therefore, I also dont know the mechanisms [underlying] how light affects them.

Prof. Charlotte Frster

The intermittent synchrony between menstrual cycles and lunar cycles is not coincidental, though, the researcher maintains. We performed sophisticated statistical tests that revealed that the intermittent synchrony does not occur by chance, she told us.

Although this new study may have opened up new avenues for research into menstrual patterns, much more work is necessary to confirm whether or not there is a synchrony with moon cycles and, if so, what biological mechanisms might be at play.

Further research should include a larger and more inclusive cohort, the investigators note in their study paper. Aside from the limited number of participants in the recent study, there was also a dearth of variance in participant diversity.

This cohort is not at all representative of the global female population, because the majority of women are white and stem from Europe, Prof. Frster told MNT.

Using a more diverse cohort is important, as previous research has suggested that menstrual cycle length may vary by race or ethnicity.

Prof. Frster believes that learning more about the environmental factors that may influence menstrual cycles could come in handy under certain circumstances.

What applications might this and further studies on this topic have, in the context of womens health? we asked her.

I think that it is still too early to [draw] conclusions. There are so many factors that influence health, and the absence of a synchronization with the moon is for sure a minor contributor to health problems, she told us.

Nevertheless, women who have difficulties [in getting] pregnant and could exclude all other medical reasons might wish to consider a more natural life without too much artificial light at night, she suggested.

See the article here:
Menstrual cycles and lunar cycles: Is there a link? - Medical News Today